Drug Discovery & Pharmaceuticals

RSS

Researchers create virtual cells to accelerate drug discovery efforts

Mitochondria - tiny structures that convert nutrients into energy - are often depicted as discrete kidney bean-shaped objects.

18 Sep 2026

Largest neuroimaging study of bulimia nervosa finds structural brain differences linked to diagnosis and binge-eating severity

Researchers at the Icahn School of Medicine at Mount Sinai found that individuals with bulimia nervosa have structural differences in brain regions involved in reward and motivation, as well as social and sensory processing, and that more frequent binge eating is associated with more widespread differences in brain structure, according to research published today in JAMA Psychiatry.

18 Sep 2026

Wildfire smoke may be more harmful than other air pollution, two Mount Sinai studies find

As climate change drives more frequent and intense wildfires, researchers at the Icahn School of Medicine at Mount Sinai have published two large-scale studies showing that wildfire smoke may pose greater health risks than other sources of air pollution, with higher risks of hospitalization for cardiovascular and respiratory disease and poorer survival among patients with lung cancer.

18 Sep 2026

Scientists discover metabolite fueling aggressive brain tumor growth

Virtually all high-grade, aggressive gliomas in adults accumulate massive amounts of a metabolite called guanidinoacetate (GAA) that overstimulates nearby neurons and promotes tumor growth, according to new research from scientists at Children’s Medical Center Research Institute at UT Southwestern (CRI) published in Cell.

18 Sep 2026

Researchers mine cobra toxins to uncover a membrane-disrupting antimicrobial peptide

Researchers combined toxin sequence mining with machine learning and deep-learning prediction tools to identify and experimentally test 14 antimicrobial peptide candidates derived from cobra cardiotoxins. Most candidates showed limited antibacterial potency, while CTX-p5 displayed moderate membrane-disrupting activity, revealing both the potential and current limitations of computationally guided venom peptide discovery.

17 Sep 2026

New indicators could accelerate development of anti-aging drugs

Twelve candidate indicators, based on studies in mice, could make developing anti-aging interventions faster-while offering new insights into age-related diseases.

17 Sep 2026

Can AI find drugs to fight infection?

Streptococcus pneumoniae is a bacterial pathogen that causes life-threatening infections, including pneumonia and meningitis.

17 Sep 2026

MGI launches VisiOmics in Europe and unveils AI-enabled pathology portfolio at ECP 2026

MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation in life science, today announced the European launch of VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence (mIF) staining and imaging system, at the 38th European Congress of Pathology (ECP 2026), held in Stockholm from 12 to 16 September 2026.

From MGI 16 Sep 2026

Insilico Medicine launches AI initiative to develop longevity vaccines

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient's own immune cells to eliminate the earliest cellular drivers of age-related disease.

15 Sep 2026

Orexo announces FDA acceptance of Investigational New Drug (IND) application for OX640 for the treatment of anaphylaxis

Orexo AB (publ.) today announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OX640, a nasally administered powder formulation of epinephrine intended for the emergency treatment of anaphylaxis.

15 Sep 2026

OutSee awarded Innovate UK grant for agentic AI pilot study to enhance drug target validation

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive approach to uncover new drug targets, today announced it has been awarded funding through Innovate UK's Investor Partnership Grant, jointly provided by Innovate UK and Empirical Ventures.

From OutSee 9 Sep 2026

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

LSD deconstruction reveals promising new drug candidates

University of California, Davis researchers have stripped down LSD to the base features responsible for its hallucinogenic and therapeutic effects.

7 Sep 2026

Experimental cancer drug could protect against osteoporosis and weight gain

An experimental cancer drug could stop osteoporosis and help women stay slim after the menopause – according to new research from the University of East Anglia.

7 Sep 2026

Generative AI helps scientists design entirely new RNA transporters

Researchers at Helmholtz Munich and TUM have developed Synthetic Transfer Vehicles (STVs), an entirely new class of RNA transporters.

2 Sep 2026

Insilico Medicine releases frontier AI models for drug discovery

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the release of a series of frontier specialist models for chemistry and biology, trained through its MMAI Gym for Science framework.

2 Sep 2026